IDEAYA Biosciences (IDYA) Receivables (2020 - 2026)
IDEAYA Biosciences (IDYA) posted Receivables of $13.1 million for Q1 2026, up 9.83% sequentially from $11.9 million in Q4 2025.
IDEAYA Biosciences (IDYA) Receivables (2020 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Receivables for 7 years, with the latest figure at $13.1 million in Q1 2026.
- Quarterly Receivables changed N/A year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (changed N/A YoY) and the FY2025 annual result came in at $11.9 million, up 398100.0% from the prior year.
- Receivables climbed to $13.1 million in Q1 2026 per IDYA's latest filing, from $11.9 million in the prior quarter.
- Over five years, Receivables peaked at $13.1 million in Q1 2026 and troughed at $1000.0 in Q2 2024.
- A 5-year average of $2.6 million and a median of $244000.0 in 2022 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2025: Receivables plunged 99.7% in 2024, then jumped 398100.0% in 2025.
- Over 5 years, Receivables stood at $200000.0 in 2022, then plunged by 91.0% to $18000.0 in 2023, then plunged by 83.33% to $3000.0 in 2024, then surged by 398100.0% to $11.9 million in 2025, then climbed by 9.83% to $13.1 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $13.1 million, $11.9 million, and $3000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | 30.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.83 Mn |
| Mar 31, 2026 | 13.12 Mn |
| Dec 31, 2025 | 11.95 Mn |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Sep 30, 2023 | 6.70 Mn |
| Jun 30, 2023 | 160,000.00 |
| Mar 31, 2023 | 468,000.00 |
| Dec 31, 2022 | 200,000.00 |
| Sep 30, 2022 | 3.45 Mn |
| Jun 30, 2022 | 288,000.00 |
| Mar 31, 2022 | 697,000.00 |
| Dec 31, 2021 | 1.10 Mn |
| Sep 30, 2021 | 1.02 Mn |
| Jun 30, 2021 | 1.33 Mn |
| Mar 31, 2021 | 2.92 Mn |
| Dec 31, 2020 | 1.90 Mn |